scholarly journals Rare Presentation of Primary Extramedullary Plasmacytoma as Lip Lesion

2017 ◽  
Vol 2017 ◽  
pp. 1-5
Author(s):  
Mali Him ◽  
Maggie Meier ◽  
Vikas Mehta

Malignant plasma cell proliferation can be presented as part of disseminated disease of multiple myeloma, as solitary plasmacytoma of bone, or in soft tissue as extramedullary plasmacytoma. Extramedullary plasmacytomas represented approximately 3% of all plasma cell proliferation. Approximately 80% of extramedullary plasmacytomas occur in the head and neck region while the other 4% occur in the skin and to a lesser extent in the lip. In this paper, we report a rare case of primary cutaneous plasmacytoma involving the lip in a 65-year-old male. The patient presented with a nonhealing lower lip sore for the past 3 years. Upon further workup, there was no evidence of multiple myeloma or light chain disease. The patient was treated with radiation therapy and his last follow-up revealed no evidence of multiple myeloma or light chain disease.

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1973-1973
Author(s):  
Seema Naik ◽  
Paul J. Shaughnessy ◽  
Behyar Zoghi ◽  
Jose C Cruz ◽  
Carlos Bachier

Abstract Introduction: Outcomes of Multiple myeloma (MM) have improved in the recent years with combination of novel agents, autologous transplants followed by maintenance therapies. One of the current challenges is to optimize transplant strategies for MM patients with extramedullary plasmacytomas (EMP). Patients and Methods: We retrospectively analyzed outcomes of 237 consecutive MM patients (M132:F105) who underwent ASCT at Texas Transplant Institute, between December 2011 and June 2014. The study was approved by Institutional Review Board. The median length of follow-up was 44.8 months (10 - 86.8 months) in all patients. Censoring date was the last clinic visit prior to December 2014. Results: A total of 237 MM patients were evaluated for presence of plasmacytomas. Patients presented either with multiple intraosseous lytic lesions (MM-IOL) without EMP (n=105; 44%); MM without lytic lesions or EMP in (n=80; 34%) and remaining MM-EMP (n=52; 22%) presented with EMP without multiple lytic lesions. Disease subtype was nonsecretory (5%; n=13), IGA (15%; n=35), IGG (56%; n=133), kappa light chain (16%; n=38) and lambda light chain (8%; n=18) for all 237 patients. (Table 1). Cytogenetics was available in 216 patients (91%) and statistically different among the 3 groups (p=0.05). The sites of EMP included the abdomen, pelvis, chest wall; liver, soft tissue, with sizes ranging from 1.8 cm 10 cm. EMP patients developed recurrent EMP after autologous transplant in 20% (10/52) cases. Fifty percent of patients with recurrent EMP (5/10) died of EMP progression. A total of 140 (59%) patients received triple drug regimens either CyBorD (n=51; 22%) or VRD (n=89; 38%) prior to transplant. Radiation therapy was given to 42 % (n=22/52) patients with EMP and only 4% patients without EMP (n=8 /185). There was no difference in OS and PFS for patients treated with 2 drugs (VD/RD) compared to 3 drug regimens (CyBorD/VRD) for either OS or PFS. Prior solitary plasmacytoma were seen more frequently in 19% patients (n=10/52) who had EMP manifestations prior to transplant. Prior MGUS /smoldering myelomas were seen in 13 % MM-IOL patients. Disease characterisitics (p=0.0515), plasma cell percentage (p=0.0119) and disease recurrence (p=<0.0001) were statistically different for OS for all 237 patients. Disease characteristics (p=0.0751) and recurrence (p=<0.0001) were prognostic for PFS. 3 year probability of OS was 82% (95% CI, 64%- 92%), 84.7% (95% CI, 72%- 92%) and 71.6% (95% CI, 53%- 84%) for patients MM without EMP, MM-IOL and MM-EMP, respectively. Conclusion: Novel therapeutic approaches including proteasome inhibitors and immunomodulatory agents followed by transplant can overcome poor prognosis of MM-EMP patients. Those that do relapse do extremely poorly suggesting need for alternative new therapies. Table 1. Patient Characteristics Variable All patients MM withoutIOL/EMP MM-IOL MM-EMP (M132:F105) (n=237)(100%) (n=80)(34%) (n=105)(44%) (n=52)(22%) Median age P=0.5038 63 (37-79) 62 (40-76) 63 (37-79) 63 (39-77) MM subtype P=0.9589 IGG subtype 133 (56%) 45(56%) 61(58%) 28(23%) IGG kappa 91 (38%) 31(39%) 42(40%) 18(4%) IGG lambda 42 (18%) 14(18%) 19(18%) 9(17%) IGA Subtype 35 (14.7%) 13(16%) 16(15.2%) 6(12%) Kappa LCD 38 (16%) 14(18%) 16(16%) 8 (15%) Lambda LCD 18 (8%) 4(5%) 8(8%) 6(12%) Nonsecretory 13 (6%) 4(5%) 4(4%) 5(10%) Prior Plasma Cell Disorder* P=0.0001 Smoldering MM* 7 (3%) 3(4%) 4(4%) 0(0%) Plasmacytoma* 13 (6%) 1(1%) 2(2%) 10(19%) MGUS* 26 (11%) 13(16%) 9(9%) 4(8%) Cytogenetics P=0.0586 Normal Cytogenetics 84(34%) 41(51%) 25(26%) 27(54%) Mono 13/13 del 22(13%) 10(13%) 20(19%) 6(12%) 17 del 4(2%) 1(1%) 3(3%) 1(2%) Trisomy 11/t(11:14) 8(3%) 6(8%) 3(3%) 6(12%) T(4:14) 5(2%) 2(2.5%) 4(4%) 2(4%) Hyperdiploidy 22(9%) 6(8%) 11(10%) 2(4%) Prior Treatments P=0.1122 CyBorD 51(22%) 19 (24%) 26(25%) 6(12%) VRD/VTD 89(38%) 27(34%) 43(41%) 18(34%) VD/RD/TD 91(38%) 30(38%) 36(34%) 24(46%) Other 6(2.5%) 3(4%) 0(0%) 3(6%) 3 yr OS (p=0.462) 86.1% (65%-95%) 91.3% (81%-96%) 83.4% (65%-93%) 3 yr PFS (p=0.1302) 82.8% (64%-92%) 84.7% (72%-92%) 71.6% (53%-84%) Disclosures Shaughnessy: pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; millenium: Honoraria, Membership on an entity's Board of Directors or advisory committees; sonofi/genzyme: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5050-5050
Author(s):  
Maged Khalil ◽  
Candice Ruby ◽  
Zili He ◽  
Shetra Sivamurthy ◽  
Steier Williams ◽  
...  

Abstract Plasma cell tumors are lymphoid neoplastic proliferations of B cells that may be classified as multiple myeloma (MM), solitary bone plasmacytoma (SBP) and extramedullary plasmacytoma (EMP). The extramedullary plasmacytoma account for 1–2% of the total number of plasma-cell growths of which 80 % are originated on the head and neck and upper airways. Males are more frequently affected at sixth-seventh decade. Herein we are presenting a case of 51 years old male with synchronous multiple extramedullary plasmacytomas involving lung, stomach and spine, Presentation of a case 51 years old black male from St. Lucia with no significant past medical history, presented to the local hospital in St. Lucia with hematemesis. Endoscopy was performed and a growth in the stomach was found. He came to the US for treatment. When seen in our hospital, patient complained of black tarry stool, severe right sided chest pain radiating to the back, generalized body aches, fatigue and 10 Lbs. weight loss within the last 2 months Physical examination: revealed tenderness on the right side of chest and back, and decreased breath sound on the righ upper lobe, otherwise unremarkable Work up including CT scan of the chest/abdomen /pelvis showed an irregular right apical mass posteriorly with destruction of the adjacent second and third ribs posteriorly and in T2 and T3 vertebrae, diffuse lytic lesions involving the spines, sacrum, ribs and sternum. There was also a large irregular soft tissue mass the posterior aspect of the fundus of the stomach. Liver, spleen and lymph nodes were normal. Laboratory studies showed WBCs 9.8, Hg 6.9, Platlets 218, BUN 71, Cr. 5.2, Ca 13.4, albumin 3.4, B2 microglobulin 7.5, TP 11.4, LDH 1063, LFT’s all normal, Cea 00 ng/ml, AFP 6.0 ng/ml, Ca19-9 9.4 U/ml, PSA.97 ng/ml, iron study, folate, B12 all within normal range, serum protein electropheresis and immunofixation showed monoclonal spike in the Gamma region 53.8% (IgG Kappa and IgA Kappa), IgG 10917 mg/dl, IgA 85 mg/dl, IgM 16 mg/dl, urine protien elctrophersis showed 88 mg/dl M-spike in beta region, 24 hours urine was 2400 mg/24 h Bone marrow biopsy showed extensive infiltration with poorly differentiated plasma cells, flow cytometry consistent with plasma cell neoplasm, cytogenetics and FISH did not show any evidence of chromosome 13 deletion or trisomy 11. Gastric mass biopsy and lung mass biopsy showed plasma cells similar to the bone marrow infiltrate consistent with plasmacytoma. Diagnosis of multiple myeloma and multiple extramedullary plasmacytomas were made. Plasmaphersis was started because of worsening renal function despite aggressive hydration. Kidney function and calcium level normalized after 5 sessions of Plasmaphersis. Chemotherapy with Doxil, Vincrestine and dexamethasone (DVd) was started. Because of the persistent drop in hemoglobin from gastric mass bleeding, Radiation therapy to the gastric area was given (2300 cGy in 4 weeks) While on treatment he developed severe bilateral lower extremities weakness, MRI showed 8 cm epidural mass at the T8 level, the field of radiation was increased to include the new lesion along with Decadron. He developed severe oral mucositis, esophagitis pancytopenia, continue to bleed from the gastric mass, and finally developed an overwhelming VRE sepsis and shock. He was transferred to MICU and expired despite aggressive supportive care. Conclusion: MM can present as multiple extramedullary plasmacytomas. The response to chemotherapy is very poor The prognosis is very poor,


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e19516-e19516
Author(s):  
Hyun Ae Jung ◽  
Chi Hoon Maeng ◽  
Jun Ho Jang ◽  
Chul Won Jung ◽  
Kihyun Kim

e19516 Background: Extramedullary plasmacytomas (EMPs) is a rare presentation of plasma cell neoplasm and accounts for 7 to 15% of all plasma cell neoplasm. Fluorescence in-situ hybridization (FISH)-detected abnormalities, including del(17p), del(13q), and t(4;14), have been associated with inferior prognosis. However, there are few data about the prognostic significance of cytogenetic abnormalities in multiple myeloma (MM) patients with EMPs. This study aimed the clinical features, FISH data and outcome of patients with EMPs Methods: The data were collected from multiple myeloma patients with EMPs, retrospectively. We excluded skeletal plasmacytomas. The clinic-pathologic variables and treatment outcome retrospectively reviewed. Results: Seventeen patients had solitary EMPs. Most common site of solitary EMP was nasal cavity and most patients received radiotherapy (n=7) and surgery (n=6). A total of 905 patients with newly diagnosed MM were included, and 53 patients (8.7 %) had EMPs at diagnosis. Thirty three patients had conventional FISH data. By conventional cytogenetic analysis and FISH, 35.8% (19/53) and 54.5% (18/33) patients were identified genetic abnormalities, respectively. By comprehensive cytogenetic/FISH approach, the most common genetic aberration was 1q21 amplification and/or 1p32 deletion (42.4%, 14/33), followed by -13 or del (13q) (24.3%, 8/33), del (17p) (15.2%, 5/33), IGH/FGFR3 rearrangement (15%, 2/33) and IGH/CCND1 rearrangement (12%, 2/33). Patients with initial EMPs had significantly worse overall survival compared to those without initial EMPs. Del(13q), and t(4;14), have been associated with inferior prognosis. Conclusions: In the current study, del(13q), and t(4;14) were associated with worse survival in MM patients with EMP.


1984 ◽  
Vol 98 (9) ◽  
pp. 929-938 ◽  
Author(s):  
Thomas A. Mustone ◽  
Marvin P. Fried ◽  
Max L. Goodman ◽  
James H. Kelly ◽  
Marshall Strome

AbstractPlasma cell neoplasms have been classified as multiple myeloma, solitary plasmacytoma and extramedullary plasmacytoma. They are usually considered as osteolytic lesions of bone except for the rare occurrence of osteosclerotic lesions. This paper describes the first reported osteosclerotic plasmacytoma of the maxillary bone and orbital floor. The difficulties in establishing a diagnosis and the relationship to other plasma cell neoplasms are discussed.Osteosclerotic plasmacytomas are a rare variant of plasma cell tumors which usually produce osteolytic lesions rather than bony sclerosis. Sixty-eight patients with the osteosclerotic variant have appeared in the world literature, with an overall incidence of about 1 per cent in a large series of plasma cell neoplasms (Dreidger and Pruzanski, 1979). There have been only six previous cases of solitary osteosclerotic plasmacytomas reported (Morley and Schweiger, 1964; Roberts et al., 1974; Rodriguez et al. 1976; Rushton, 1965; Schneinker, 1938; Brigham Medical Review, 1961) involving spine, sternum, or rib. None have previously been reported in the head and neck area.Plasma cell tumors have been classified into multiple myeloma, solitary plasmacytomas of bone, and extramedullary plasmacytomas. Multiple myeloma is a disseminated plasma cell malignancy characterized by the production of homogeneous immunoglobulins (whole or fragments) which appear in the serum and urine. Plasma cell tumors can also occur as solitary plasmacytomas, usually in bone, but also in soft tissue. With time, most solitary plasmacytomas develop disseminated disease with all the characteristics of multiple myeloma (Wiltshaw, 1976). Extramedullary plasmacytomas arise in soft tissue rather than bone, and primarily occur in the head and neck region. Clinically, they remain localized and less frequently develop into disseminated myeloma.


Author(s):  
Shrinath Kamath ◽  
Deepika Pratap ◽  
Kishore Chandra Shetty ◽  
Biniyam .

<p>Extramedullary plasmacytomas (EMPs) are localized plasma cell neoplasms that occur within the soft tissue. Solitary plasmacytoma of the head and neck is a rare disease entity. They account for 1–2% of all plasma cell growths and have a great predilection for the upper respiratory tract. Males are more frequently affected during the fifth and sixth decades of life. We report a case of maxillary sinus plasmacytoma in an elderly man. Complete resolution of the tumour was seen with radiotherapy. </p>


1983 ◽  
Vol 92 (3) ◽  
pp. 311-313 ◽  
Author(s):  
John G. Batsakis

In order of frequency, the plasma cell lesions affecting the head and neck are multiple myeloma, extramedullary plasmacytoma, plasma cell granuloma, and solitary plasmacytoma of bone. All except plasma cell granuloma are neoplastic and they are interrelated. The solitary plasmacytoma of bone is regarded as a form of multiple myeloma. The extramedullary plasmacytoma may be a lesion of local significance only or may terminate in a disseminated disease, myelomatosis, that differs clinically and prognostically from multiple myeloma.


2016 ◽  
Vol 32 (1) ◽  
pp. 39-42
Author(s):  
Md Atikur Rahman ◽  
Aklaque Hossain Khan ◽  
Kanak Kanti Barua

Primary craniocerebral plasmacytomas are uncommon and represent only 0.7 % of all plasmacytomas. In this case solitary plasmacytoma in the midline frontal head region of the skull and discuss the clinical features and prognosis of this tumor. Plasmacytoma can present as multiple myeloma, solitary plasmacytoma of the bone or extramedullary plasmacytoma. Solitary plasmacytoma is a rare entity that composes of malignant plasma cells and involves the bone to form only one or two lesions without evidence of disease dissemination. It accounts for only 4% of malignant plasma cell tumors. 50 years old male was suffering from plasmacytoma in the frontal head region in our case which is pulsatile. On images showed multiple differential diagnosis but after operation histological examination revealed plasmacytoma. Bangladesh Journal of Neuroscience 2016; Vol. 32 (1): 39-42


2001 ◽  
Vol 125 (8) ◽  
pp. 1078-1080 ◽  
Author(s):  
Annarosaria De Chiara ◽  
Simona Losito ◽  
Luigi Terracciano ◽  
Raimondo Di Giacomo ◽  
Giancarla Iaccarino ◽  
...  

Abstract We describe a solitary extramedullary plasmacytoma of the breast in a 37-year-old woman. No other involvement was detected in the bone marrow or in any other site during a 15-month follow-up period. Extramedullary plasmacytomas of the breast are extremely rare, especially those that are not associated with multiple myeloma. We review the histologic features of the previously reported cases with an emphasis on differential diagnosis and the difficulties encountered in arriving at the correct diagnosis in frozen sections.


2019 ◽  
Vol 3 (5) ◽  
pp. 744-750 ◽  
Author(s):  
Nidhi Tandon ◽  
Surbhi Sidana ◽  
S. Vincent Rajkumar ◽  
Morie A. Gertz ◽  
Francis K. Buadi ◽  
...  

Abstract We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with ≥VGPR and &lt;VGPR after 2 cycles (PFS, 28 vs 30 months, P = .6; OS, 78 vs 96 months, P = .1) and 4 cycles (PFS, 31 vs 29 months; OS, 89 vs 91 months, P = .9), although both were improved, with ≥VGPR as best response (PFS, 33 vs 22 months, P &lt; .001; OS, 102 vs 77 months, P = .003). On multivariate analysis stratified by transplant status, achievement of ≥VGPR after 2 cycles was not associated with improved PFS (hazard ratio [95% confidence interval]; transplant cohort, 1.1 [0.7-1.6]; nontransplant cohort, 1.2 [0.8-1.7]) or OS (transplant cohort, 1.6 [0.9-2.9]; nontransplant cohort, 1.5 [1.0-2.4]). Covariates in the model included high-risk cytogenetics, ISS stage III, triplet therapy, creatinine ≥2 mg/dL, light chain disease, and age. Although patients with high-risk disease are more likely to achieve early response, a rapid achievement of a deep response by itself does not affect long-term outcomes.


Sign in / Sign up

Export Citation Format

Share Document